Alexion, 澳门在线赌城娱乐罕见病, enters agreement with Pfizer to acquire a portfolio of preclinical rare disease gene therapies

Agreement furthers Alexion’s ambition to transform patient outcomes with genomic medicine and provides synergistic opportunities across 澳门在线赌城娱乐

Portfolio includes preclinical gene therapy programmes and enabling technologies with potential across several therapeutic areas
 

Alexion, 澳门在线赌城娱乐罕见病, today announced that it has entered a definitive purchase and licence agreement for a portfolio of preclinical gene therapy programmes and enabling technologies from Pfizer 公司. (辉瑞). The agreement furthers Alexion and 澳门在线赌城娱乐’s commitment to advancing next-generation genomic medicines with the addition of complementary pipeline assets and innovative technologies.

作为协议的一部分, the transaction will bring to Alexion a number of novel adeno-associated virus (AAV) capsids. AAV capsids have been shown to be an effective mechanism for delivering therapeutic gene cargos for gene therapy and gene editing.¹ These new resources build on Alexion and 澳门在线赌城娱乐’s combined capabilities in genomic medicine, recently strengthened with the acquisition of LogicBio, with the objective to develop new genetic therapies with improved safety and efficacy profiles. Additionally, Alexion will seek to welcome talent from Pfizer associated with the portfolio.

Marc Dunoyer, 首席执行官, Alexion, 澳门在线赌城娱乐罕见病, said: “Today’s announcement represents another major step forward in Alexion and 澳门在线赌城娱乐’s ambition to be an industry leader in genomic medicine, which has potential to be transformative and even curative for patients with devastating diseases. We look forward to continuing our work to develop enhanced platforms and technologies with broad therapeutic application while integrating best-in-class expertise to accelerate promising therapeutics into the clinic.”

不止7个,000种已知罕见疾病, and around 80% of rare diseases are believed to be caused by a genetic mutation.^2,3 Genomic medicines are designed to treat or cure these diseases by addressing the malfunctioning gene. 这可以通过加法来实现, alteration or inactivation of the gene to help the body fight the disease.⁴

金融方面的考虑
根据协议, Alexion will purchase and licence the assets of Pfizer’s early-stage rare disease gene therapy portfolio for a total consideration of up to $1bn, 加上销售的分级版税.

Alexion plans to close the transaction in Q3 2023, subject to the satisfaction of closing conditions.

笔记

Alexion
Alexion, 澳门在线赌城娱乐罕见病, is the group within 澳门在线赌城娱乐 focused on rare diseases, created following the 2021 acquisition of Alexion Pharmaceuticals, 公司. As a leader in rare diseases for nearly 30 years, Alexion is focused on serving patients and families affected by rare diseases and devastating conditions through the discovery, 发展 and commercialisation of life-changing medicines. Alexion focuses its research efforts on novel molecules and targets in the complement cascade and its 发展 efforts on haematology, 肾脏学, 神经学, 代谢紊乱, 心脏病学和眼科. 总部设在波士顿, 麻萨诸塞州, Alexion has offices around the globe and serves patients in more than 50 countries.

澳门在线赌城娱乐
澳门在线赌城娱乐 (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, 发展, and commercialisation of prescription medicines in 肿瘤学, 罕见疾病, 和澳门第一赌城在线娱乐, 包括心血管, 肾 & 新陈代谢和呼吸 & 免疫学. 总部设在剑桥, UK, 澳门在线赌城娱乐 operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. 请访问 澳门在线赌城娱乐.com 并在推特 @上关注公司澳门在线赌城娱乐.

联系人
For details on how to contact the 投资者关系 Team, please click 在这里. 对于“媒体联系人”，单击 在这里.

参考文献。

艾德里安·坎普
公司秘书
澳门在线赌城娱乐